Ad26.ZEBOV monovalent vaccine based on adenovirus type 26 (Ad26) vector expressing the glycoprotein (GP) of the Ebola virus Mayinga variant (Ad26.ZEBOV) was developed by Crucell Holland N.V. (now called Janssen Vaccines & Prevention, B.V.), one of the Janssen Pharmaceutical Companies of Johnson & Johnson
Ad26.ZEBOV/MVA-BN a heterologous prime-boost Ebola vaccine regimen contains two components: Janssen’s AdVac® technology (based on adenovirus type 26) and MVA-BN® technology based on Modified Vaccinia Ankara virus.
These vaccines both use a viral vector approach, where a virus is genetically modified so that it cannot replicate but is used to safely express key proteins of the target virus, in this case, Ebola virus. Prime-boost vaccination is an established approach for the prevention of other infectious diseases.
Clinical Trial: NCT03929757 A Phase 2 Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
Clinical Trial: NCT02543567 A Phase 3 Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants